Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone
A recent phase II clinical trial has shown that combined [...]
Deciding on the ideal first-line treatment for rare and advanced kidney cancer
Currently, doctors are unsure which is the best first-line treatment [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer
A recent phase 1b clinical trial investigated the use of [...]
ESMO 2019: ADAPTeR study to evaluate the role of nivolumab before and after surgery – results of biomarker analysis
Results from the ADAPTeR study to evaluate the role of [...]
ESMO 2019: Results from TITAN-RCC tailored immunotherapy clinical trial
Results from the TITAN-RCC clinical trial to assess tailored immunotherapy [...]
Nivolumab demonstrates long term survival in advanced kidney cancer
A new study published in JAMA Oncology shows that treatment [...]
Nivolumab and kidney cancer brain metastases
Results from a recent trial suggest that nivolumab has limited [...]
Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases
An interim analysis of study Checkmate 920 has shown that [...]
SMC approves nivolumab plus ipilimumab combination for advanced RCC
We are delighted to announce that the Scottish Medicines Consortium [...]
